Risk factors
Cytosorbents (CTSO) risk factors
Item 1A of every Cytosorbents Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors32 risks8 new14 dropped9 reworded
Cytosorbents faces intense regulatory setbacks with FDA and Health Canada denials for DrugSorb-ATR.
Filed Mar 30, 2026 - FY2024 10-K risk factors38 risks
Cytosorbents faces heavy accumulated losses and requires ongoing capital raises to fund its cash burn operations. Commercial success depends heavily on the CytoSorb device, particularly within its primary German market. Intellectual property protection, international regulations, and third-party reimbursement strictly dictate commercial viability.
Filed Mar 31, 2025